Srini Ramanathan
Corporate Officer/Principal chez ROIVANT SCIENCES LTD.
Profil
Srini Ramanathan is currently the Chief Development Officer at Roivant Sciences Ltd.
Prior to this, he worked as the Senior VP-Research & Development Sciences at Horizon Therapeutics Plc.
He holds a doctorate degree from Rutgers State University of New Jersey and a graduate degree from Duquesne University School of Law.
Postes actifs de Srini Ramanathan
| Sociétés | Poste | Début |
|---|---|---|
| ROIVANT SCIENCES LTD. | Corporate Officer/Principal | 02/05/2022 |
Anciens postes connus de Srini Ramanathan
| Sociétés | Poste | Fin |
|---|---|---|
| HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Corporate Officer/Principal | - |
Formation de Srini Ramanathan
| Rutgers State University of New Jersey | Doctorate Degree |
| Duquesne University School of Law | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ROIVANT SCIENCES LTD. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Horizon Therapeutics Plc
 Horizon Therapeutics Plc Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. | Health Technology |
